New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints ...

TARRYTOWN, N.Y. and PARIS, June 15, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps ( CRSwNP ) and coexisting asthma.

EAACI: Dupixent demonstrated superiority over Xolair ( omalizumab ) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study ...

EAACI: Dupixent demonstrated superiority over Xolair ( omalizumab ) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Investors Urged to Contact Levi & Korsinsky for Information Before August 1, 2025 - Fortrea Holdings Inc. ...

Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action ...

Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August ...

Levi & Korsinsky Urges PepGen Inc. (PEPG) Shareholders to Act Before Lead Plaintiff Deadline August ...

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Zenas BioPharma, Inc. ...

Lost Money on Krispy Kreme, Inc. (DNUT)? Urged to Join Class Action Before July 15, 2025 - Contact Levi ...